Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02741440 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 160 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Eligibility criteria expanded, about 10 words
  2. Minor 7 versions Re-verified since Jul 22, 2026, no change to tracked fieldsv153-v159
  3. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment reduced: 25 → 22 participants
    v152
  4. Minor 35 versions Re-verified since May 20, 2023, no change to tracked fieldsv117-v151
  5. Minor Study description revisedv116
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv115
  2. Minor Study Status, Study Description, Eligibilityv114
  3. Notable Primary and study completion dates: Jan 1, 2027 to Dec 31, 2028v113
  4. Minor 2 versions Re-verified since Jul 27, 2022, no change to tracked fieldsv111-v112
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to collect vision and neurology related data from people with SCA7. They want to learn how and what changes in the eye and brain when the ATXN7 gene isn t working properly. Objective: To learn more about SCA7 and its progression. Eligibility: People ages 12 and older with SCA7. Design: Participants will be screened with medical history and genetic testing from a previous National Eye Institute study or their personal physician. Participants will have at least 7 visits over 5 years. They will have 2 visits during the first week of the study. Then they will be asked to come back every year for the next 5 years. Each visit will last several days and will include: * Medical and eye history * Several eye tests: some will include dilating the pupil with eye drops and taking photos or scans of the eyes. * Electroretinography (ERG): Participants will sit in the dark with their eyes patched for 30 minutes. After this, the patches will be removed and contact lenses put into the eyes. They will watch flashing lights and information will be recorded. * Neurological exams: Sensation, strength, coordination, reflexes, attention, memory, language, and other cognitive functions will be tested. * Brain MRI: They will lie in a machine that takes pictures of the brain. * Blood and urine tests * Optional skin biopsy: About 3 millimeters of skin will be removed for more research testing; this is half the size of a pencil eraser.
Trial Details
NCT Number NCT02741440
Lead Sponsor National Eye Institute (NEI)
Conditions
(from sponsor)
Spinocerebellar Ataxia
Related terms Spinocerebellar Ataxias
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov